๋ฒค์กฐ๋””์•„์ œํ•€ ๋ถˆ์‘์„ฑ ๊ฒฝ๋ จ์„ฑ ๊ฐ„์งˆ์ง€์†์ƒํƒœ / Benzodiazepine-refractory convulsive status epilepticus

์ •์˜

Benzodiazepine-refractory established convulsive status epilepticus๋Š” benzodiazepine ํˆฌ์—ฌ ํ›„์—๋„ ๊ฒฝ๋ จ์ด ์ง€์†๋˜๋Š” ๊ฐ„์งˆ์ง€์†์ƒํƒœ๋ฅผ ์˜๋ฏธํ•œ๋‹ค.

์ž„์ƒ ํ•ต์‹ฌ

๋‹จ์ˆœ ๋ฐœ์ž‘ ํ›„ AED loading๊ณผ ๋‹ฌ๋ฆฌ, ongoing convulsion ๋˜๋Š” BZD ํ›„ ์ง€์†๋˜๋Š” established SE์—์„œ๋Š” 2์ฐจ ์•ฝ์ œ ํ”„๋กœํ† ์ฝœ๋กœ ์ ‘๊ทผํ•œ๋‹ค. ์ตœ๊ทผ ED ๊ทผ๊ฑฐ์—์„œ๋Š” levetiracetam 60 mg/kg IV, ์ตœ๋Œ€ 4.5 g ์šฉ๋Ÿ‰์ด ์‚ฌ์šฉ๋œ๋‹ค. ์ด ์šฉ๋Ÿ‰์€ ESETT trial์—์„œ fosphenytoin, valproate์™€ ๋น„๊ต๋œ levetiracetam ์šฉ๋Ÿ‰์ด๋‹ค.

์ง„๋‹จ

ํ•ต์‹ฌ ํŒ๋‹จ์€ ํ˜„์žฌ ๊ฒฝ๋ จ์ด ์ง€์† ์ค‘์ธ์ง€, benzodiazepine ํˆฌ์—ฌ ํ›„์—๋„ ๋ฉˆ์ถ”์ง€ ์•Š์•˜๋Š”์ง€์ด๋‹ค. ๋‹จ์ˆœ postictal ์ƒํƒœ์—์„œ ๋ฉŽ์€ ๋ฐœ์ž‘๊ณผ ๊ตฌ๋ถ„ํ•ด์•ผ ํ•œ๋‹ค.

์น˜๋ฃŒ

2์ฐจ ์•ฝ์ œ๋กœ levetiracetam์„ ์‚ฌ์šฉํ•  ๋•Œ๋Š” 60 mg/kg IV, max 4.5 g๋ฅผ ๊ณ ๋ คํ•œ๋‹ค. ์ด๋Š” ์ผ๋ฐ˜์ ์ธ seizure loading ์šฉ๋Ÿ‰์ธ 20 mg/kg๋ณด๋‹ค ๋†’์€ SE protocol ์šฉ๋Ÿ‰์ด๋‹ค.

์ถœ์ฒ˜

AES convulsive SE guideline 2016; ESETT NEJM 2019.

๐ŸŒฑ ์ถœ์ฒ˜ raw


๋ณธ ๋ฌธ์„œ๋Š” ํ•™์Šตยท์ฐธ๊ณ ์šฉ์ด๋ฉฐ ์‹ค์ œ ์ง„๋ฃŒ ๊ฒฐ์ •์€ ์ž„์ƒ์˜์˜ ํŒ๋‹จ์ž…๋‹ˆ๋‹ค.

๐Ÿ“ ์ถ”๊ฐ€ (2026-05-15, source: 2026-05-15-1155-ae63fd91-q2.md)

์ •์˜

Benzodiazepine-refractory convulsive status epilepticus๋Š” ์ถฉ๋ถ„ํ•œ benzodiazepine ์ดˆ๊ธฐ์น˜๋ฃŒ ํ›„์—๋„ convulsive seizure๊ฐ€ ์ง€์†๋˜๋Š” ์ƒํƒœ์ด๋‹ค.

์ž„์ƒ ํ•ต์‹ฌ

์ดˆ๊ธฐ benzodiazepine ์น˜๋ฃŒ ํ›„์—๋„ ์ง€์†๋˜๋ฉด second therapy phase๋กœ ๋„˜์–ด๊ฐ„๋‹ค. 2์ฐจ ์•ฝ์ œ ์„ ํƒ์ง€๋Š” fosphenytoin, valproate, levetiracetam ์ค‘ ํ•˜๋‚˜์ด๋‹ค. Levetiracetam์„ ์„ ํƒํ•  ๊ฒฝ์šฐ 60 mg/kg IV, ์ตœ๋Œ€ 4.5 g loading์„ ์‚ฌ์šฉํ•œ๋‹ค. ESETT trial์—์„œ๋Š” ์„ธ ์•ฝ์ œ์˜ efficacyยทsafety๊ฐ€ ์œ ์‚ฌํ•œ ๊ฒƒ์œผ๋กœ ์ œ์‹œ๋˜์—ˆ๋‹ค.

์ง„๋‹จ

์ง€์†์ ์ธ convulsive seizure๊ฐ€ ์žˆ๊ณ , ์ด๋ฏธ ์ถฉ๋ถ„ํ•œ benzodiazepine์ด ํˆฌ์—ฌ๋˜์—ˆ๋Š”์ง€๊ฐ€ ํ•ต์‹ฌ ๋ถ„๊ธฐ์ ์ด๋‹ค.

์น˜๋ฃŒ

Second-line ํ•ญ๊ฒฝ๋ จ์ œ๋ฅผ ์ง€์ฒด ์—†์ด ํˆฌ์—ฌํ•œ๋‹ค. Levetiracetam์€ ๋ณดํ†ต ์•ฝ 10๋ถ„ infusion์œผ๋กœ ํˆฌ์—ฌํ•œ๋‹ค. ์ดํ›„์—๋„ ๋ฐœ์ž‘์ด ์ง€์†๋˜๋ฉด refractory status epilepticus๋กœ ๊ฐ„์ฃผํ•˜๊ณ  intubation/sedation ๋ฐ ICU pathway๋ฅผ ์ง„ํ–‰ํ•œ๋‹ค.

์ถœ์ฒ˜

AES CSE guideline์€ benzodiazepine ์ดˆ๊ธฐ์น˜๋ฃŒ ํ›„ second therapy phase๋ฅผ ๊ถŒ๊ณ ํ•œ๋‹ค. ESETT trial์€ levetiracetam, fosphenytoin, valproate๋ฅผ ๋น„๊ตํ–ˆ๋‹ค.

๐Ÿ“ ์ถ”๊ฐ€ (2026-05-15, source: 2026-05-15-1155-ae63fd91-q1.md)

์ •์˜

๋ฒค์กฐ๋””์•„์ œํ•€ ๋ถˆ์‘์„ฑ ๊ฒฝ๋ จ์„ฑ ๋‡Œ์ „์ฆ์ง€์†์ƒํƒœ๋Š” ์ดˆ๊ธฐ benzodiazepine ์น˜๋ฃŒ ํ›„์—๋„ ์ „์‹  ๊ฒฝ๋ จ์„ฑ ๋ฐœ์ž‘์ด ์ง€์†๋˜๋Š” ์ƒํƒœ์ด๋‹ค.

์ž„์ƒ ํ•ต์‹ฌ

์ง„๋‹จ

์ง€์†์ ์ธ convulsive seizure ๋˜๋Š” ํšŒ๋ณต ์—†์ด ๋ฐ˜๋ณต๋˜๋Š” ๋ฐœ์ž‘์„ ํ‰๊ฐ€ํ•˜๊ณ , ์ดˆ๊ธฐ benzodiazepine ์น˜๋ฃŒ ๋ฐ˜์‘ ์—ฌ๋ถ€๋กœ refractory ์—ฌ๋ถ€๋ฅผ ํŒ๋‹จํ•œ๋‹ค.

์น˜๋ฃŒ

์ถœ์ฒ˜